Skip to main content

Advertisement

SpringerLink
Log in

Estrogen deficiency and bone loss in women with breast cancer

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

The Original Article was published on 05 August 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ramaswamy B, Shapiro CL (2003) Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 30(6):763–775

    Article  CAS  PubMed  Google Scholar 

  2. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359(9321):1929–1936

    Article  PubMed  Google Scholar 

  3. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385–397

    Article  CAS  PubMed  Google Scholar 

  4. Chen Z, Maricic M, Aragaki AK, Mouton C, Arendell L, Lopez AM, Bassford T, Chlebowski RT (2009) Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women’s Health Initiative. Osteoporos Int 20(4):527–536

    Article  CAS  PubMed  Google Scholar 

  5. Imai Y, Kondoh S, Kouzmenko A, Kato S (2010) Minireview: osteoprotective action of estrogens is mediated by osteoclastic estrogen receptor-alpha. Mol Endocrinol 24(5):877–885

    Article  CAS  PubMed  Google Scholar 

  6. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840–849

    Article  CAS  PubMed  Google Scholar 

  7. Pant S, Shapiro CL (2008) Aromatase inhibitor-associated bone loss: clinical considerations. Drugs 68(18):2591–2600

    Article  CAS  PubMed  Google Scholar 

  8. Molina JR, Barton DL, Loprinzi CL (2005) Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf 28(5):401–416

    Article  CAS  PubMed  Google Scholar 

  9. Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19(14):3306–3311

    CAS  PubMed  Google Scholar 

  10. Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman AB, Josse R, Kaiser S, Olszynski WP, Papaioannou A et al (2006) Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum 36(1):22–31

    Article  PubMed  Google Scholar 

  11. Felsenberg D, Boonen S (2005) The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27(1):1–11

    Article  PubMed  Google Scholar 

  12. Hadjidakis DJ, Androulakis II (2006) Bone Remodeling. Ann N Y Acad Sci 1092(1):385–396

    Article  CAS  PubMed  Google Scholar 

  13. Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332(5):305–311

    Article  CAS  PubMed  Google Scholar 

  14. Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29(2):155–192

    Article  CAS  PubMed  Google Scholar 

  15. Boyce BF, Xing L (2007) The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 5(3):98–104

    Article  PubMed  Google Scholar 

  16. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5(6):618–625

    Article  CAS  PubMed  Google Scholar 

  17. Manolagas SC, Kousteni S, Jilka RL (2002) Sex steroids and bone. Recent Prog Horm Res 57:385–409

    Article  CAS  PubMed  Google Scholar 

  18. Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116(5):1186–1194

    Article  CAS  PubMed  Google Scholar 

  19. Imai Y, Youn M-Y, Kondoh S, Nakamura T, Kouzmenko A, Matsumoto T, Takada I, Takaoka K, Kato S (2009) Estrogens maintain bone mass by regulating expression of genes controlling function and life span in mature osteoclasts. Ann N Y Acad Sci 1173(S1):E31–E39

    Article  CAS  PubMed  Google Scholar 

  20. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M (2008) Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27(3):535–545

    Article  CAS  PubMed  Google Scholar 

  21. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y et al (2007) Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130(5):811–823

    Article  CAS  PubMed  Google Scholar 

  22. Weitzmann MN, Pacifici R (2005) Role of the immune system in postmenopausal bone loss. Curr Osteoporos Rep 3(3):92–97

    Article  PubMed  Google Scholar 

  23. Weitzmann MN, Pacifici R (2007) T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci 1116:360–375

    Article  CAS  PubMed  Google Scholar 

  24. Zallone A (2006) Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci 1068:173–179

    Article  CAS  PubMed  Google Scholar 

  25. Weitzmann MN, Pacifici R (2005) The role of T lymphocytes in bone metabolism. Immunol Rev 208:154–168

    Article  CAS  PubMed  Google Scholar 

  26. Lea CK, Flanagan AM (1999) Ovarian androgens protect against bone loss in rats made oestrogen deficient by treatment with ICI 182, 780. J Endocrinol 160(1):111–117

    Article  CAS  PubMed  Google Scholar 

  27. Fogelman I, Blake GM, Blamey R, Palmer M, Sauerbrei W, Schumacher M, Serin D, Stewart A, Wilpshaar W (2003) Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14(12):1001–1006

    Article  CAS  PubMed  Google Scholar 

  28. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15(4):1341–1347

    CAS  PubMed  Google Scholar 

  29. Crandall C, Petersen L, Ganz PA, Greendale GA (2004) Bone mineral density and adjuvant therapy in breast cancer survivors. Breast Cancer Res Treat 88(3):257–261

    Article  CAS  PubMed  Google Scholar 

  30. Greep NC, Giuliano AE, Hansen NM, Taketani T, Wang HJ, Singer FR (2003) The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 114(8):653–659

    Article  PubMed  Google Scholar 

  31. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17(8):2365–2370

    CAS  PubMed  Google Scholar 

  32. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583–2592

    Article  CAS  PubMed  Google Scholar 

  33. Shapiro CL, Phillips G, Van Poznak CH, Jackson R, Leboff MS, Woodard S, Lemeshow S (2005) Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 90(1):41–46

    Article  CAS  PubMed  Google Scholar 

  34. Chen Z, Arendell L, Aickin M, Cauley J, Lewis CE, Chlebowski R (2008) Hip bone density predicts breast cancer risk independently of Gail score: results from the Women’s Health Initiative. Cancer 113(5):907–915

    Article  PubMed  Google Scholar 

  35. Termine JD, Wong M (1998) Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health. Maturitas 30(3):241–245

    Article  CAS  PubMed  Google Scholar 

  36. Shapiro CL, Halabi S, Gibson G et al (2008) Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809. J Clin Onc 26 (May 20 Suppl; abstract 512)

  37. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw 7(Suppl 3):S1–S32 (quiz S33–S35)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ohio State University Medical Center, James Cancer Hospital, Columbus, OH, 43210, Canada

    Charles L. Shapiro

Authors
  1. Charles L. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles L. Shapiro.

Additional information

This is an invited commentary to article doi:10.1007/s10549-010-0899-7

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shapiro, C.L. Estrogen deficiency and bone loss in women with breast cancer. Breast Cancer Res Treat 123, 815–818 (2010). https://doi.org/10.1007/s10549-010-1099-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1099-1

Keywords

Search

Navigation